This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (38)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

An Analysis of 51 Patients Evaluated in the United States and Japan

Henry W. Lim, MD; Warwick L. Morison, MD; Ryoichi Kamide, MD; Mary Ruth Buchness, MD; Ross Harris, MD; Nicholas A. Soter, MD

Arch Dermatol. 1994;130(10):1284-1289.

Abstract
Background and Design
We studied the clinical and photobiologic features of 51 patients with chronic actinic dermatitis who were evaluated at three institutions. The following criteria for patient selection were used: (1) a persistent eczematous eruption in the sun-exposed areas of greater than 3 months' duration; (2) decreased phototest results; and (3) when available, histologic changes of a dermal infiltrate of lymphocytes and macrophages, with or without epidermal spongiosis and atypical mononuclear cells in the dermis and epidermis.

Results
The 51 patients had a mean age of 62.7 years, a male-to-female ratio of 2.6:1, and a mean duration of eruption of 5.8 years. The most common abnormal results of the phototests were decreased minimal erythema doses to both UV-A and UV-B, followed by decreased minimal erythema doses to UV-A alone. Patients with abnormally low responses to UV-A or visible light and normal minimal erythema doses to UV-B had the same clinical profile as the overall patient population. Aside from protection from sunlight, treatment modalities that have been used include PUVA (8-methoxypsoralen and UV-A) photochemotherapy, azathioprine, hydroxychloroquine sulfate, and, for recalcitrant cases, cyclosporine.

Conclusions
Chronic actinic dermatitis is a persistent photodermatosis associated with abnormal phototest responses to UV-A, and/or UV-B, and/or increased sensitivity to visible light; histopathologic changes are consistent with photodermatitis. Treatment consists of combinations of topical and oral medications.

(Arch Dermatol. 1994;130:1284-1289)

Author Affiliations
From the Dermatology Service, New York (NY) Veterans Affairs Medical Center (Drs Lim, Buchness, and Harris); the Photomedicine Section, Charles C. Harris Skin and Cancer Pavilion, the Ronald O. Perelman Department of Dermatology, New York University School of Medicine (Drs Lim, Buchness, Harris, and Soter); the Department of Dermatology, The Johns Hopkins Medical Institutions, Baltimore, Md (Dr Morison); and the Department of Dermatology, Jikei University School of Medicine, Tokyo, Japan (Dr Kamide).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Photosensitivity
Morison
NEJM 2004;350:1111-1117.
FULL TEXT  

Safety Assessment of Dichlorophene and Chlorophene
International Journal of Toxicology 2004;23:1-27.
ABSTRACT | FULL TEXT  

Diltiazem-Associated Photodistributed Hyperpigmentation: A Review of 4 Cases
Scherschun et al.
Arch Dermatol 2001;137:179-182.
ABSTRACT | FULL TEXT  

The Natural History of Chronic Actinic Dermatitis
Dawe et al.
Arch Dermatol 2000;136:1215-1220.
ABSTRACT | FULL TEXT  

Mycophenolate in Psoralen-UV-A Desensitization Therapy for Chronic Actinic Dermatitis
Nousari et al.
Arch Dermatol 1999;135:1128-1129.
FULL TEXT  

Allergic Contact and Photoallergic Contact Dermatitis to Plant and Pesticide Allergens
Mark et al.
Arch Dermatol 1999;135:67-70.
ABSTRACT | FULL TEXT